Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharma (NQ: PIRS )

1.800 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.800
Bid (Size) 1.710 (4)
Ask (Size) 1.890 (4)
Prev. Close 1.800
Today's Range 1.800 - 1.800
52wk Range 0.8464 - 3.650
Shares Outstanding 74,406,253
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Via ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Via ACCESSWIRE

Performance

YTD
+65.14%
+65.14%
1 Month
+40.62%
+40.62%
3 Month
+71.43%
+71.43%
6 Month
+12.50%
+12.50%
1 Year
-48.72%
-48.72%

More News

Read More
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
Via ACCESSWIRE
Recap: Pieris Pharmaceuticals Q3 Earnings
Via Benzinga
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate
Via Benzinga
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Recap: Pieris Pharmaceuticals Q1 Earnings
Via Benzinga
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
Via ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
Via ACCESSWIRE
Pieris Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
Via Benzinga
Pieris Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Pieris Pharmaceuticals's Earnings Outlook
Via Benzinga
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
Via ACCESSWIRE
Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
From Pieris Pharmaceuticals, Inc.
Via AccessWire
4 Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.